8-K - Evofem Biosciences, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Evofem Biosciences, Inc. and Windtree Therapeutics, Inc. entered into a Termination Agreement on March 13, 2026, mutually terminating their License and Supply Agreement (originally dated March 20, 2025, and amended) with no termination fees payable. Certain customary survival provisions of the original agreement remain in effect, and Windtree must cease using the company's IP and return confidential information.

Key Takeaways

1Termination Agreement effective March 13, 2026, between Evofem Biosciences, Inc. and Windtree Therapeutics, Inc.

2Terminates License and Supply Agreement dated March 20, 2025 (amended March 28, 2025) for PHEXXI® manufacturing and supply

3No termination fees or other payments due to either party

4Windtree to immediately cease using Buyer Specifications, Assets, Confidential Information, and Intellectual Property

5Customary survival provisions from Section 11.6 of the original agreement remain in effect

Current Report Details

Event Type

Material Agreement

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.02

. Termination of Material Definitive Agreement. As previously disclosed in Current Reports on Form 8-K dated March 26, 2025 and April 3, 2025, on March 20, 2025

Material Agreement

Source Document

9.01

. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Termination Agreement by and between the Company and Windtree Therapeutics, Inc.

Exhibits Only

Transaction Details

Material Agreement

Agreement: Termination Agreement
Parties: Evofem Biosciences, Inc., Windtree Therapeutics, Inc.

•Mutual termination of License and Supply Agreement effective March 13, 2026
•No fees payable in connection with termination
•Supplier to cease using and return Buyer IP, assets, and confidential information
•Survival of sections listed in Section 11.6 of License and Supply Agreement

Exhibits (2)

10.1

EX-10.1

8-K